Navigation Links
Bay Area Youth to Represent ALS Patients at Giants' and Angels' Baseball Games on July 4th
Date:7/3/2009

S TDI, Augie's Quest (the Muscular Dystrophy Association's ALS research initiative) and Project A.L.S. -- whose primary goal is to find a cure for ALS. The initiative will culminate on July 4, 2009, which is the 70th anniversary of Lou Gehrig's famous farewell speech at Yankee Stadium. ALS destroys the nerve cells controlling muscles, ultimately causing complete paralysis. Average life expectancy is three to five years after diagnosis.

"Corey is an amazing and positive young man. He and his family have impacted us greatly at ALS TDI. We are very lucky to have an opportunity to know him and have his family's support for our work. It is heartbreaking that there is so little that can be done for young men and women like Corey today. That is unacceptable, and we must not stop until we have a better answer for all ALS patients," said Steve Perrin, Ph.D., Chief Executive Officer and Chief Scientific Officer at ALS TDI.

Although Corey is a life-long Oakland Athletics fan, he and his father Ted, mother Wendy, and sister Clare, will take part in a pre-game celebration honoring Lou Gehrig and ALS patients that are currently battling the disease at the start of the San Francisco Giants game. Corey will then board a plane to Anaheim to arrive just before game time at the "Big A" to see the Angels play the Baltimore Orioles. At the Angels' game, Corey will again enter onto the field with other ALS patients to repeat a similar ceremony in the Angels' stadium and then spend the rest of the day with other ALS patients and advocates attending the game as well.

More information on Corey and his efforts can be found online at www.coreyscrusaders.alscommunity.org. The "4ALS Awareness" campaign is a joint effort between four ALS organizations; the ALS Association, the MDA/Augie's Quest, Project ALS, and ALS TDI. More information is available on the Off
'/>"/>

SOURCE ALS Therapy Development Foundation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Encision Enters Into Sales Representation Agreement With Caldera Medical
2. Air Transport Association Applauds House of Representatives on Decision to Withhold Biometric Collection Funding
3. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
4. CMR Institute: Education Key to Physician/Representative Relationship
5. Microfluidic Systems to Show Automated Biological Agent Detection Technology to U.S. House of Representatives
6. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
7. Experts and Representatives From Leading International Health-Care Organizations Call to Stop the Hypertension Pandemic, a Worldwide Silent Killer
8. ThalesNano Inc. Opens Own Representation in the United Kingdom and has New Distribution Agreements for Europe and India
9. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
10. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
11. Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... Chief Executive Officer of Neurocrine Biosciences, will be presenting ... The live presentation takes place on Tuesday, ... will be webcast and may be accessed on the ... Listeners are encouraged to visit the website approximately 5 ...
(Date:3/3/2015)... , March 3, 2015  Regenicin, Inc. (OTC ... specializing in the development of and commercialization of regenerative ... and organs, announced today that it has received the ... Amarantus Bioscience Holdings, Inc. (OTC Bulletin Board: ... Agreement, Amarantus made the final payments due to Regenicin ...
(Date:3/3/2015)... March 3, 2015  Thingee Corporation, a software development ... a presentation entitled, "Technology Adoption: Making Reps, Lives Easier" ... Innovations and Technology ,  in Deerfield Beach, ... 13, 2015. Audiences looking to learn how technology can ... to be in the audience for the Thingee presentation. ...
(Date:3/3/2015)... Switzerland (PRWEB) March 03, 2015 ... for drug discovery and life science research, today ... Biologics (TM) enterprise platform for use at Pfizer ... and Europe. Genedata is supporting Pfizer’s global deployment ... Technologies (GBT), Centers for Therapeutic Innovation (CTI), and ...
Breaking Biology Technology:Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Thingee to present at 11th Annual Synergistix Users Conference 2Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3
... R-Tech Ueno, Ltd. announced on July 29 after discussing its R&D ... the day and determined the R&D items as follows. , ... the ophthalmologic & dermatological fields that are its priority and exclusive ... , 1. Development code UF-021 (eye diseases) , ...
... , , SAN DIEGO, July 30 ... the protocol for the Company,s Phase II trial of ANA598 in combination ... the protocol has been received from the United States Food and Drug ... several weeks. , , In the Phase II study, ...
... , , SEATTLE, July 30 Trubion ... to issue earnings results for its second quarter and six months ended ... The company,s earnings conference call will take place Aug. 6, 2009 at ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO ) , , The ...
Cached Biology Technology:R-Tech Ueno Notifies R&D Items 2R-Tech Ueno Notifies R&D Items 3Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 2Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 3Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 4Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 5Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call 2
(Date:2/12/2015)... OXFORD, Conn. , Feb. 12, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62/113114 for ... MULTIPLE DEVICES. The patent further establishes NXT-ID,s ... to its intellectual property portfolio the ability for multiple ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
(Date:2/5/2015)... DIEGO , Jan. 26, 2015   Epic Sciences ... of cancer, today announced that Murali Prahalad , Ph.D., ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, which ... Mountain View, Calif. on January 26-28, 2015. ... "CTCs Come of Age as Biomarkers." Last year, Epic Sciences ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... flowers have evolved particular colours, shapes and scents ... using artificial flowers and high-speed video, researchers have ... hummingbirds and the flowers they pollinate. The study, ... Functional Ecology , is the first to measure ...
... grey seal mums adopt risky tactics when it comes to the ... a real advantage, according to scientists. Researchers from Durham University, ... colonies in Scotland, found that some seal mothers are flexible in ... their actions, whilst other play it safe and steady. ...
... Calif.) When your neighbor asks to borrow a cup of ... of the give and take that characterize your longstanding relationship? Or ... of sugar you borrowed last week, or may need to borrow ... anthropology at UC Santa Barbara, and a junior research fellow at ...
Cached Biology News:High-speed video and artificial flowers shed light on mysteries of hummingbird-pollinated flowers 2Seals gamble with their pups' futures 2Seals gamble with their pups' futures 3UCSB anthropologist studies reciprocity among chimpanzees and bonobos 2UCSB anthropologist studies reciprocity among chimpanzees and bonobos 3
amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2...
IKKbeta/IKK-2 Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Reacts with human. Tested in Western blotting....
... RACE (rapid amplification of cDNA ends) technique ... 5' and 3' cDNA ends. The GeneRacer ... Transcriptase (RT) for improved amplification of the ... mRNA. The RNase H portion of SuperScript ...
activating transcription factor 4 (tax-responsive enhancer element B67),...
Biology Products: